“We have gone through challenging times where we made every effort to fine tune all the production processes. Therefore, we know the difficulties behind the implementation like no one else. It’s not so easy e.g. to tune up the equipment without any help from foreign colleagues who have vast experience in this area and considering the complexity of IT solutions.

Nanolek was one of the first pharmaceutical providers in the market to produce a labelled drug series. This happened in November 2019.
Currently, our biotechnological production cluster in Kirov manufactures labelled drugs “Hunterase” (supplied as part of the cost-intensive nosology program (VZN)) and “Fraxiparine”, and is gearing up for the production of a labelled series of combined vaccine “Pentaxime®” to satisfy the needs of the National vaccination calendar.

Notwithstanding the fact that we are entirely prepared for supplies of labelled products, the coronavirus pandemic is reshuffling plans, and based on that we support the request by the Association of Russian pharmaceutical manufacturers (ARFP) to postpone the launch of mandatory labelling. The current situation around COVID-19 constitutes a force majeure and largely affected the introduction of labelling at many pharmaceutical companies.

Therefore, keeping in mind that we support the idea of labelling (it will definitely help track the movement of pharmaceuticals at every stage and protect the end user by making the market completely transparent), we are ready to join the working party together with representatives of the Association of Russian pharmaceutical manufacturers (ARFP) and help our colleagues regarding any questions arising. We can look back on extensive experience and have well-trained employees”, said Maxim Stetsyuk, Executive Director of NANOLEK.